PROCEPT BioRobotics (NASDAQ:PRCT) Price Target Cut to $30.00 by Analysts at Leerink Partners

PROCEPT BioRobotics (NASDAQ:PRCT) had its target price dropped by analysts at Leerink Partners from $55.00 to $30.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ price target points to a potential upside of 26.90% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Oppenheimer reaffirmed a “market perform” rating on shares of PROCEPT BioRobotics in a research note on Thursday. UBS Group assumed coverage on PROCEPT BioRobotics in a research note on Friday, December 12th. They set a “buy” rating and a $62.00 price objective on the stock. Bank of America downgraded shares of PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and decreased their target price for the company from $38.00 to $20.00 in a research note on Thursday. Piper Sandler dropped their price objective on PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, Wells Fargo & Company cut their target price on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $43.60.

PROCEPT BioRobotics Trading Down 15.1%

Shares of NASDAQ PRCT traded down $4.20 during midday trading on Thursday, reaching $23.64. 7,353,204 shares of the stock were exchanged, compared to its average volume of 1,382,187. The stock has a 50 day moving average price of $30.37 and a 200-day moving average price of $33.71. The company has a current ratio of 8.44, a quick ratio of 7.20 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $1.32 billion, a P/E ratio of -15.46 and a beta of 0.99. PROCEPT BioRobotics has a 52-week low of $19.35 and a 52-week high of $68.70.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The firm had revenue of $76.38 million for the quarter, compared to analyst estimates of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The firm’s revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.35) EPS. Equities research analysts expect that PROCEPT BioRobotics will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PROCEPT BioRobotics

Hedge funds have recently made changes to their positions in the business. Alliancebernstein L.P. lifted its position in shares of PROCEPT BioRobotics by 58.6% during the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after acquiring an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in PROCEPT BioRobotics by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after buying an additional 1,218,815 shares in the last quarter. Westfield Capital Management Co. LP increased its position in PROCEPT BioRobotics by 23.3% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,970,147 shares of the company’s stock worth $70,315,000 after purchasing an additional 371,798 shares during the last quarter. Mackenzie Financial Corp raised its position in PROCEPT BioRobotics by 8.2% during the fourth quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock valued at $49,512,000 after acquiring an additional 118,971 shares in the last quarter. Finally, Chicago Capital LLC lifted its stake in shares of PROCEPT BioRobotics by 175.7% in the 3rd quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock valued at $55,992,000 after purchasing an additional 999,873 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: TD Cowen cut its price target to $34 but kept a “buy” rating, still implying material upside from current levels — a vote of confidence that the stock can recover if execution improves. TD Cowen Lowers PT to $34
• Positive Sentiment: PROCEPT hosted an Investor Day outlining a multi‑year strategic plan and 2026–2027 financial outlook aimed at driving long‑term growth, which could support sentiment if management delivers on targets. Investor Day Release
• Neutral Sentiment: Piper Sandler trimmed its target to $28 but kept an “overweight” rating — reduces upside expectations but maintains constructive stance. Piper Sandler PT Cut
• Neutral Sentiment: Oppenheimer reaffirmed a “market perform” rating, leaving some analyst views unchanged amid the mixed signals. Oppenheimer Reaffirms Rating
• Neutral Sentiment: Management’s FY‑2026 revenue guidance of $390M–$410M is slightly above consensus, which could be a modest positive if the company demonstrates trajectory toward those targets. FY‑2026 Guidance
• Negative Sentiment: Q4 results missed badly: EPS of ($0.53) vs. consensus ($0.32) and revenue $76.4M vs. $93.7M expected — a near‑term shock to expectations. Q4 Results & Call
• Negative Sentiment: Q1 revenue guidance was cut sharply to $79M–$82M (well below the ~$93.7M consensus), raising concerns about near‑term growth and driving the immediate sell‑off. Q1 Revenue Guide
• Negative Sentiment: Bank of America downgraded PRCT to “underperform” and cut its target to $20, reflecting increased downside risk from the earnings/guidance miss. BofA Downgrade
• Negative Sentiment: Coverage noting PRCT hit a 52‑week low highlights the market reaction to the mix of weak quarterly results and guidance. 52‑Week Low Coverage

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.